Press Room

Latest

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001


Latest News

Uscom SpiroSonic Devices for Spanish Health Project

June 1st, 2017

Spanish eHealth monitoring of patients with chronic disease using digital Uscom SpiroSonic spirometers and software platform

Uscom subsidiary Uscom Europe announced a partnership with Sonmedica S.A., the Public Health Agency of Catalonia and the Health Campus of the University of Barcelona to deliver telemetric pulmonary care via the Nextcare Digital Health Care Project to patients in Catalonia. The project, the first of its kind worldwide, aims to deliver personalised home care to patients with chronic disease via a public digital health care framework.

The pulmonary arm of the Nextcare project is being led by Professor Josep Roca, MD, PhD, the Director of The Lung Function Unit at the Barcelona Hospital Clinic, Professor of Medicine at The University of Barcelona, and the former president of the European Respiratory Society credited with over 470 peer reviewed publications.

The pulmonary arm of the Nextcare project uses the new Uscom SpiroSonic tSpiro telemetric ultrasonic spirometers for the home care monitoring of patients with chronic pulmonary disease. The Uscom SpiroSonic devices utilise multi-path ultrasonic technology and are wirelessly connected to the central hospital record keeping systems with Uscom SpiroReporter proprietary digital phone and cloud based software applications. Specialist pulmonologists then evaluate the measurements and direct management via mobile phone, thus by-passing expensive hospital treatment.

Key Points

  • The Nextcare digital health care project is designed to provide digital home care monitoring for patients with chronic diseases, including asthma and COPD
  • Pulmonary diseases such as asthma and COPD are increasing worldwide as air quality deteriorates
  • Uscom tSpiro multi-path ultrasonic spirometers provide practice leading pulmonary function measurements
  • Uscom proprietary software and digital connectivity with SpiroSonic devices provides for high acuity home care monitoring of pulmonary function
  • As part of the Nextcare program approximately 50 Uscom tSpiro devices have been deployed and connected to regional hospital medical recording systems as part of the pilot study, while the system is expected to be rolled out state wide over the next few years as its clinical value is established.
  • The pulmonary arm of the Nextcare project is the first worldwide to implement telemetric pulmonary care into the eHealth home care model
  • The Uscom tSpiro platform of devices are currently being adopted by a number of eHealth providers around the world and are approved for European sales, and are currently being reviewed for US FDA and Chinese CFDA approval.
  • The Nextcare Digital Health Care Project is supported by European Union funding

Uscom’s Global Head of Product Innovation and Digital Pulmonary Devices, George Ferenczi said: “Our engineering team have spent a lot of time working with Sonmedica and the scientists in the Nextcare program at the University of Barcelona matching the digital interfaces of our SpiroSonic devices with the Catalonian Hospital medical records systems and ensuring ease of digital communication and simplification of signal analysis.”

Executive Chairman of Uscom, Associate Professor Rob Phillips said: “Our digital health work with the Barcelona University and Public Health Agency of Catalonia is the first of its kind worldwide, and will become the template for digital health care worldwide; this project is setting the standards for eHealth excellence for the future. It’s a great credit to our Uscom engineers that this innovative model has been so seamlessly implemented for the benefit of the people of this highly developed region of Spain, and we look forward to the adoption of our digital technologies in similar models worldwide.”

Digital cloud based pulmonary monitoring is an emerging global trend in clinical care, and provides for early detection of changes in pulmonary function and improved guidance of therapy. This collaboration between the Public Health Agency of Catalonia, the Health Campus of the University of Barcelona, and Sonmedica with Uscom Europe is supported by European Union funding, and is further recognition of the superior quality of the SpiroSonic digital spirometers and our connectivity solutions. While many current spirometers use mechanical turbines, Uscom’s patented multi-path ultrasonic spirometers provide higher accuracy, lower maintenance, are simpler to use, and are more hygienic.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

References:

http://blog.aquas.cat/wp-content/uploads/2016/12/Catalunya-2016-Reference-Sites.pdf

Uscom SpiroSonic Devices for French Lung Transplant Study

June 1st, 2017

Uscom has announced a partnership with French Company Aqsitania SAS to use the new Uscom SpiroSonic tSpiro telemetric pulmonary function devices for the monitoring and improved management of lung transplant patients. The tSpiro devices are advanced multi-path ultrasonic spirometers that connect wirelessly to personal communication devices, and ultimately web based software applications to monitor and analyse respiratory function allowing cost effective home care monitoring.

Key Points

  • Lung transplantation is expensive and requires on going pulmonary functional monitoring
  • Uscom tSpiro multi-path ultrasonic spirometers provide practice leading pulmonary function measurements
  • Uscom digital connectivity allows for home care monitoring of lung transplantation patients
  • Aqsitania SAS is a French Company specialising in eHealth applications of advanced signal analysis and modelling particularly of respiratory function and development of Personal Respiratory Profiles (PRPs)
  • Aqsitania have purchased approximately 100 Uscom tSpiro devices for the pilot project, with further orders for several hundred devices anticipated for the second phase of the project
  • The Uscom tSpiro platform of devices are currently under consideration for use by a number of digital telemetric asthma and COPD solution companies around the world developing cloud based monitoring and diagnosis software and analytics models
  • tSpiro devices are approved for European sales, and are currently being submitted for US FDA and Chinese CFDA approval.
  • The Aqsitania SAS Lung Transplantation project is supported by European Union funding.

Uscom’s Global Head of Digital Pulmonary Devices, George Ferenczi said, “Our new SpiroSonic tSpiro devices deliver research quality digital ultrasonic telemetric spirometry into the home care market, allowing specialist monitoring of pulmonary function in the patient’s home, providing more effective management and reducing expensive hospital attendances. Application of tSpiro for monitoring and guiding management of lung transplantation patients is new, and expands our established application in Asthma, COPD and Occupation Lung Disease.”

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Digital telemetric spirometry is the future of pulmonary medicine and we are at the forefront of this field. Aqsitania SAS is a world leader in pulmonary function signal analysis, and their algorithms depend on the highest quality spirometry sensors. We are delighted they are using Uscom tSpiro devices for their program to improve the care of lung transplants patients. We are already leaders in digital cloud based home care for asthma and COPD and Occupational Lung Disease Monitoring, and this is a further clinical application for our new SpiroSonic devices.”

Digital cloud based pulmonary monitoring is an emerging global trend in clinical care, and provides for early detection of changes in pulmonary function and improved guidance of therapy. This collaboration between Aqsitania SAS and Uscom Europe is supported by European Union funding is recognition of the superior quality of the SpiroSonic digital spirometers.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

References:

http://www.aqsitania.com

Uscom boosts global sales and marketing

May 1st, 2017

New global Sales and Marketing Manager appointed to support release of new products.

Left to Right: Denise Pater, Damien Linnett and Rob Phillips

Uscom today announced the appointment of Damien Linnett to the position of Global Sales and Marketing Manager. Mr Linnett is an economics graduate from the University of Queensland, with an MBA in international marketing. He has over 20 years’ global medical device sales and marketing management experience.

Damien Linnett has previously held executive positions with international corporations Datex-Ohmeda and Spacelabs Healthcare, and most recently with Kinetic Concepts Inc. (KCI Medical), an Acelity Company. Mr Linnett joins the growing sales, marketing and distribution division of Uscom to accommodate and advance the increased product suites of Uscom devices.

Uscom has completed the development of the new BP+ and SpiroSonic devices and now has them in regulatory cycles, awaiting multiple jurisdiction approvals in China (CFDA), Europe (CE) and USA (FDA). The focus of the sales, marketing and distribution division will be to sign up new specialist distributors, manage the sale of the new devices, and grow the new revenue streams.

Mr Linnett said, “Uscom is a business in transformation as it approaches profitability with 7 new standard of care products due for imminent release to market. For me that represents an opportunity to accelerate global sales and revenue growth. Uscom has a growing international reputation as a corporation and manufacturer of premium medical devices with a great foundation product and rapidly growing market share. I’m looking forward to being a part of the Uscom growth story, and adding my skills to those of the current team to accelerate sales as we bring these new and exciting products to market.”

Uscom CEO Associate Professor Rob Phillips said, “Uscom sales have grown by over 60% CAGR over the last 3 years, we have acquired 2 companies, and are poised for the imminent release of 7 new products into the Chinese, European and US markets. We currently manage approximately 35 distributors globally and this number will grow, with 10 new distributors signed up and awaiting the release of the BP+ devices. Having someone of Damien’s outstanding capabilities and experience join our team to guide our new products into the market is ideal. Our continued growth requires experienced management and a strong and capable sales, marketing and distribution strategy, and Damien’s contribution to our global sales, marketing and distribution division will be central to Uscom’s future commercial success.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The devices and technologies are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD diagnosis and medication monitoring.